Revolutionizing the Garment Industry 5.0: Embracing Closed-Loop Design, E-Libraries, and Digital Twins

This study presents an innovative approach for modernizing the garment industry through the fusion of digital human modeling (DHM), virtual modeling for fit sizing, ergonomic body-size data, and e-library resources. The integration of these elements empowers manufacturers to revolutionize their clothing design and production methods, leading to the delivery of unparalleled fit, comfort, and personalization for a wide range of body shapes and sizes. DHM, known for its precision in representing human bodies virtually and integrating anthropometric data, including ergonomic measurements, enhances the shopping experience by providing valuable insights. Consumers gain access to the knowledge necessary for making tailored clothing choices, thereby enhancing the personalization and satisfaction of their shopping experience. The incorporation of e-library resources takes the garment design approach to a data-driven and customer-centric level. Manufacturers can draw upon a wealth of information regarding body-size diversity, fashion trends, and customer preferences, all sourced from e-libraries. This knowledge supports the creation of a diverse range of sizes and styles, promoting inclusivity and relevance. Beyond improving garment fit, this comprehensive integration streamlines design and production processes by reducing the reliance on physical prototypes. This not only enhances efficiency but also contributes to environmental responsibility, fostering a more sustainable and eco-friendly future for the garment industry and embracing the future of fashion, where technology and data converge to create clothing that authentically fits, resonates with consumers, and aligns with the principles of sustainability. This study developed the mobile application integrating with the information in cloud database in order to present the best-suited garment for the user

A Multi-Center Study on the Efficacy of Eltrombopag in Management of Refractory Chronic Immune Thrombocytopenia: A Real-Life Experience

Objective: The aim of the present study was to evaluate the efficacy and safety of eltrombopag, an oral thrombopoietin receptor agonist, in patients with chronic immune thrombocytopenia (ITP)

A Multi-Center Study on the Efficacy of Eltrombopag in Management of Refractory Chronic Immune Thrombocytopenia: A Real-Life Experience

Objective: The aim of the present study was to evaluate the efficacy and safety of eltrombopag, an oral thrombopoietin receptor agonist, in patients with chronic immune thrombocytopenia (ITP). Materials and Methods: A total of 285 chronic ITP patients (187 women, 65.6 \%; 98 men, 34.4\%) followed in 55 centers were enrolled in this retrospective cohort. Response to treatment was assessed according to platelet count (/mm(3)) and defined as complete (platelet count of >100,000/mm(3)), partial (30,000-100,000/mm(3) or doubling of platelet count after treatment), or unresponsive (<30,000/mm(3)). Clinical findings, descriptive features, response to treatment, and side effects were recorded. Correlations between descriptive, clinical, and hematological parameters were analyzed. Results: The median age at diagnosis was 43.9 +/- 20.6 (range: 3-95) years and the duration of follow-up was 18.0 +/- 6.4 (range: 6-28.2) months. Overall response rate was 86.7\% (n=247). Complete and partial responses were observed in 182 (63.8\%) and 65 (22.8\%) patients, respectively. Thirty-eight patients (13.4\%) did not respond to eltrombopag treatment. For patients above 60 years old (n=68), overall response rate was 89.7\% (n=61), and for those above 80 years old (n=12), overall response rate was 83\% (n=10). Considering thrombocyte count before treatment, eltrombopag significantly increased platelet count at the 1st, 2nd, 3rd, 4th, and 8th weeks of treatment. As the time required for partial or complete response increased, response to treatment was significantly reduced. The time to reach the maximum platelet levels after treatment was quite variable (1-202 weeks). Notably, the higher the maximum platelet count after eltrombopag treatment, the more likely that side effects would occur. The most common side effects were headache (21.6\%), weakness (13.7\%), hepatotoxicity (11.8\%), and thrombosis (5.9\%). Conclusion: Results of the current study imply that eltrombopag is an effective therapeutic option even in elderly patients with chronic ITP. However, patients must be closely monitored for response and side effects during treatment. Since both response and side effects may be variable throughout the follow-up period, patients should be evaluated dynamically, especially in terms of thrombotic risk factors